| Not Yet Recruiting | Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors NCT06724042 | InSilico Medicine Hong Kong Limited | Phase 1 |
| Not Yet Recruiting | Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts. NCT07524140 | Eilean Therapeutics | Phase 1 |
| Not Yet Recruiting | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy NCT07423117 | IntoCell, Inc | Phase 1 |
| Recruiting | A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour NCT07213830 | Ipsen | Phase 1 / Phase 2 |
| Not Yet Recruiting | Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced NCT07086768 | Lei Zheng | Phase 1 |
| Recruiting | A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Ac NCT07213817 | Ipsen | Phase 1 / Phase 2 |
| Recruiting | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors NCT07284186 | Plexium, Inc. | Phase 1 |
| Withdrawn | Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Ma NCT04294875 | J Ints Bio | EARLY_Phase 1 |
| Recruiting | Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors NCT07156253 | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Phase 1 |
| Not Yet Recruiting | Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors NCT07088588 | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Phase 1 |
| Recruiting | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors NCT06974110 | MOMA Therapeutics | Phase 1 |
| Recruiting | Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410 | Yuhan Corporation | Phase 1 / Phase 2 |
| Terminated | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With NCT06682806 | Prelude Therapeutics | Phase 2 |
| Recruiting | A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors NCT06952010 | Exelixis | Phase 1 |
| Recruiting | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advan NCT07172802 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With A NCT06657144 | Coherus Oncology, Inc. | Phase 1 |
| Recruiting | A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors NCT06803680 | BeiGene | Phase 1 |
| Recruiting | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation NCT06778863 | Clasp Therapeutics, Inc. | Phase 1 |
| Recruiting | Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors NCT06358677 | University of Utah | Phase 2 |
| Recruiting | Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Imm NCT06587295 | National Cancer Centre, Singapore | Phase 1 |
| Not Yet Recruiting | Subjects With Advanced or Metastatic Solid Tumor Malignancies NCT05474859 | Xenthera, Inc. | Phase 1 |
| Recruiting | Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors NCT06666270 | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Phase 1 |
| Withdrawn | A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and NCT05828303 | Turning Point Therapeutics, Inc. | Phase 1 |
| Terminated | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMAR NCT06560645 | Prelude Therapeutics | Phase 1 |
| Active Not Recruiting | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors NCT06607185 | Eli Lilly and Company | Phase 1 |
| Terminated | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metasta NCT06630247 | Exelixis | Phase 1 |
| Recruiting | A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors NCT06561685 | Eli Lilly and Company | Phase 1 |
| Terminated | A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic So NCT06540066 | BeiGene | Phase 1 |
| Recruiting | Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 NCT06235437 | Ascendo Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor NCT06415487 | Acepodia Biotech, Inc. | Phase 1 |
| Recruiting | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies NCT06577987 | Circle Pharma | Phase 1 |
| Active Not Recruiting | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors NCT06545942 | MOMA Therapeutics | Phase 1 |
| Recruiting | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Soli NCT06440005 | Angiex, Inc. | Phase 1 |
| Recruiting | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) NCT06521554 | Nuvalent Inc. | Phase 1 |
| Recruiting | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069 | Eli Lilly and Company | Phase 1 |
| Recruiting | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or NCT06548672 | Biocity Biopharmaceutics Co., Ltd. | Phase 1 |
| Recruiting | A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer NCT06163391 | SOTIO Biotech AG | Phase 1 |
| Recruiting | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors NCT06302621 | Massachusetts General Hospital | Phase 1 |
| Active Not Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and O NCT06253195 | BeiGene | Phase 1 |
| Recruiting | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors NCT05983523 | PharmaEngine | Phase 1 |
| Unknown | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (M NCT05872867 | Wellmarker Bio | Phase 1 |
| Active Not Recruiting | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors NCT06238479 | Eli Lilly and Company | Phase 1 |
| Recruiting | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors NCT06244771 | Frontier Medicines Corporation | Phase 1 / Phase 2 |
| Recruiting | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors NCT06171750 | Ankyra Therapeutics, Inc | Phase 1 |
| Recruiting | A Study of KK2269 in Adult Participants With Solid Tumors NCT06266299 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Recruiting | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastat NCT06108050 | Jazz Pharmaceuticals | Phase 1 |
| Terminated | IL-2 PET Imaging in Advanced Solid Tumours NCT05471271 | University Medical Center Groningen | N/A |
| Active Not Recruiting | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring NCT05919537 | Hummingbird Bioscience | Phase 1 |
| Unknown | A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors NCT06270706 | Pliant Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) NCT05862324 | Triumvira Immunologics, Inc. | Phase 1 / Phase 2 |
| Terminated | BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors NCT05935098 | BeiGene | Phase 1 |
| Recruiting | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors NCT05875168 | Daiichi Sankyo | Phase 1 / Phase 2 |
| Recruiting | A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue NCT05837767 | Memorial Sloan Kettering Cancer Center | N/A |
| Active Not Recruiting | Study of ART6043 in Advanced/Metastatic Solid Tumors Patients NCT05898399 | Artios Pharma Ltd | Phase 1 / Phase 2 |
| Recruiting | Study of LP-184 in Patients With Advanced Solid Tumors NCT05933265 | Lantern Pharma Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Co NCT05824975 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Recruiting | Combination Therapy in Cancers With Mutations in DNA Repair Genes NCT05694715 | University of California, San Francisco | Phase 1 |
| Active Not Recruiting | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer NCT05678010 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic NCT05673928 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 M NCT05639751 | Prelude Therapeutics | Phase 1 |
| Unknown | A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations NCT05769075 | TYK Medicines, Inc | Phase 1 |
| Recruiting | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981 | Sairopa B.V. | Phase 1 |
| Recruiting | High Definition Medicine for Solid Tumors Oncology NCT06590506 | Centro Nacional de Investigaciones Oncologicas CARLOS III | — |
| Active Not Recruiting | A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours NCT05717348 | Elpiscience (Suzhou) Biopharma, Ltd. | Phase 1 |
| Active Not Recruiting | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Ad NCT05076552 | Tachyon Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cem NCT05259709 | Regeneron Pharmaceuticals | Phase 1 |
| Completed | EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity NCT05809557 | Masonic Cancer Center, University of Minnesota | N/A |
| Terminated | A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors NCT05631327 | Jazz Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS NCT05688280 | Immunophotonics, Inc. | Phase 1 / Phase 2 |
| Unknown | PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tu NCT05530200 | Second Affiliated Hospital of Soochow University | Phase 2 |
| Unknown | PraG With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid Tumors NCT05435768 | Second Affiliated Hospital of Soochow University | — |
| Withdrawn | A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advance NCT05828277 | Turning Point Therapeutics, Inc. | Phase 1 |
| Terminated | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mu NCT05480865 | Navire Pharma Inc., a BridgeBio company | Phase 1 |
| Recruiting | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrange NCT05384626 | Nuvalent Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) i NCT05479812 | Werewolf Therapeutics, Inc. | Phase 1 |
| Unknown | Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patient NCT05232409 | Valley Health System | Phase 1 |
| Unknown | A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors NCT05268666 | Jubilant Therapeutics Inc. | Phase 1 / Phase 2 |
| Terminated | Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors NCT05126433 | Jazz Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in T NCT05103358 | Aadi Bioscience, Inc. | Phase 2 |
| Completed | Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors NCT05279690 | Icahn School of Medicine at Mount Sinai | Phase 1 |
| Active Not Recruiting | Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population NCT05863052 | University of Oklahoma | — |
| Terminated | A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas NCT05490043 | Antengene (Hangzhou) Biologics Co., Ltd. | Phase 1 |
| Active Not Recruiting | LAG3 PET Imaging in Advanced Solid Tumors NCT04706715 | University Medical Center Groningen | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab NCT05081609 | Ascendis Pharma Oncology Division A/S | Phase 1 / Phase 2 |
| Recruiting | A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearra NCT05118789 | Nuvalent Inc. | Phase 1 / Phase 2 |
| Terminated | A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas NCT04986865 | Antengene Biologics Limited | Phase 1 |
| Completed | A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours NCT04914117 | RemeGen Co., Ltd. | Phase 1 |
| Unknown | A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancie NCT05028478 | Curon Biopharmaceutical (Australia) Co Pty Ltd | Phase 1 / Phase 2 |
| Terminated | A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRA NCT05071183 | Turning Point Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer NCT05004116 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Terminated | A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NCT04849273 | Turning Point Therapeutics, Inc. | Phase 1 |
| Unknown | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors NCT04801095 | Wellmarker Bio | Phase 1 |
| Active Not Recruiting | QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors NCT04898543 | ImmunityBio, Inc. | Phase 1 |
| Terminated | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors NCT04892017 | Deciphera Pharmaceuticals, LLC | Phase 1 |
| Completed | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors NCT04761198 | Mereo BioPharma | Phase 1 / Phase 2 |
| Terminated | A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid NCT04799054 | Ascendis Pharma Oncology Division A/S | Phase 1 / Phase 2 |
| Terminated | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors NCT04579757 | Hutchmed | Phase 1 / Phase 2 |
| Unknown | Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors NCT04602702 | Sunnybrook Health Sciences Centre | — |
| Unknown | The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors NCT04614740 | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 / Phase 2 |
| Terminated | Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient NCT04393454 | Albert Einstein College of Medicine | Phase 2 |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid T NCT04419532 | Daiichi Sankyo | Phase 1 |
| Terminated | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors NCT04383210 | Elevation Oncology | Phase 2 |
| Active Not Recruiting | Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) NCT04447651 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | — |
| Completed | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tum NCT04474470 | TyrNovo Ltd. | Phase 1 / Phase 2 |
| Recruiting | Safety and Early Signs of Efficacy of IL12-L19L19. NCT04471987 | Philogen S.p.A. | Phase 1 |
| Terminated | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or M NCT04161391 | Turning Point Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator ( NCT04137900 | TopAlliance Biosciences | Phase 1 |
| Active Not Recruiting | Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors NCT03964727 | Gilead Sciences | Phase 2 |
| Unknown | A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progr NCT04761744 | Korean Cancer Study Group | Phase 2 |
| Unknown | PREcision Medicine in Cancer in Odense, Denmark NCT05385081 | Odense University Hospital | N/A |
| Completed | Study Evaluating Treatment Adherence in Patients Treated With Oral Targeted Therapy in Oncology Supported by a NCT03263416 | Institut Claudius Regaud | N/A |
| Unknown | HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic So NCT03284502 | Hanmi Pharmaceutical Company Limited | Phase 1 |
| Completed | A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors NCT02133625 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies NCT01393509 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors NCT01390818 | EMD Serono | Phase 1 |
| Completed | Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors NCT00611468 | Accelerated Community Oncology Research Network | Phase 1 |
| Completed | Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors NCT00997529 | Beth Israel Deaconess Medical Center | N/A |